TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas

Publication date: 15 June 2024Source: Life Sciences, Volume 347Author(s): Si-yue Lou, Fan-li Zheng, Yong-mei Tang, Ya-nan Zheng, Jun Lu, Hai An, En-jun Zhang, Sun-liang Cui, Hua-jun Zhao

Volver